[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585746":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":73,"collaborators":10,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":10,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":10,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":10,"overallStatus":92,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"ARCE Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non Interventional",null,"All subjects with AML or MDS who are enrolled in a parent study and were exposed to ARD103 CAR-T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.",[13],"Other: Non interventional study",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","Non interventional study","Non Intervention, an observation LTFU study",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"ARCE Therapeutics, Inc ARCE","CONTACT","+886-2-26581868","contact@arcetherapeutics.com",[27,45,58],{"facility":28,"status":10,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Novant Health Cancer Institute","Charlotte","North Carolina","28204","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-80.84313,35.22709,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":10,"email":44},"Kunal Shah","980-302-6297","kashah@novanthealth.org",{"facility":28,"status":10,"city":46,"state":30,"zip":47,"country":32,"countryCode":33,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Winston-Salem","27201",{"type":35,"coordinates":49},[50,51],-80.24422,36.09986,{"lat":51,"lon":50},[54],{"name":55,"role":23,"phone":56,"phoneExt":10,"email":57},"Gait Jordan","336-718-8553","PJordan@novanthealth.org",{"facility":59,"status":10,"city":60,"state":61,"zip":62,"country":32,"countryCode":33,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":35,"coordinates":64},[65,66],-95.36327,29.76328,{"lat":66,"lon":65},[69],{"name":70,"role":23,"phone":71,"phoneExt":10,"email":72},"Dr. Abhishek Maiti","713-745-3228","AMaiti@mdanderson.org",{"type":74,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585746","a-long-term-follow-up-study-of-patients-with-ard103-car-t-cell-therapies-100585746",false,"NCT06906380","A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1\u002F2 Study and Treated With ARD103 CAR-T Cell Therapies","Inclusion Criteria:\n\n* The participant has R\u002FR AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.\n* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria for this study","ALL",{"count":84,"type":85},49,"ESTIMATED","OBSERVATIONAL","This study will evaluate the long-term safety of ARD103 cellular therapies",[89,90,91],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia, in Relapsed or Refractory","MDS (Myelodysplastic Syndrome)","NOT_YET_RECRUITING","2025-12-04",{"date":95,"type":96},"2025-12-08","ACTUAL",{"date":98,"type":85},"2026-03-15",{"date":100,"type":85},"2040-10-31",{"name":5,"class":6},3]